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In the past decade several studies comparing the in vitro
chromosome aberration test (CAT) and the in vitro micro-
nucleus test (MNT) were performed. A high correlation was
observed in each of the studies (>85%); however, no formal
validation for the micronucleus in vitro assay had been
carried out. Therefore, a working group was established by
the European Centre for the Validation of Alternative
Methods (ECVAM) to perform a retrospective validation of
the existing data, in order to evaluate the validity of the in
vitro MNTon the basis of the modular validation approach.
Theprimaryfocusofthisretrospectivevalidationwasonthe
evaluation of the potential of the in vitro MNTas alternative
tothestandardinvitroCAT.Theworkinggroupevaluated,in
a ﬁrst step, the available published data and came to the
conclusion that two studies [German ring trial, von der
Hude, W., Kalweit, S., Engelhardt, G. et al. (2000) In-vitro
micronucleus assay with Chinese hamster V79 cells: results
of a collaborative study with 26 chemicals. Mutat. Res., 468,
137–163, and SFTG International Collaborative Study,
Lorge, E., Thybaud, V., Aardema, M., Oliver, J., Wataka,
A., Lorenzon, G. and Marzin, D. (2006) SFTG International
CollaborativeStudyonin-vitro micronucleustestI. General
conditions and overall conclusions of the study. Mutat. Res.,
607, 13–36] met the criteria for a retrospective validation
according to the criteria previously deﬁned by the working
group. These two studies were evaluated in depth (including
the reanalysis of raw data) and provided the information
required for assessing the reliability (reproducibility) of the
test. For the assessment of the concordance between the in
vitro MNT and the in vitro CAT, additional published data
were considered. Based on this retrospective validation, the
ECVAMValidationManagementTeamconcludedthatthein
vitro MNT is reliable and relevant and can therefore be used
as an alternative method to the in vitro CAT. Following peer
review, these conclusions were formally endorsed by the
ECVAM Scientiﬁc Advisory Committee.
Introduction
The in vitro micronucleus test (MNT) is used by academics,
industry and contract laboratory organizations for internal
hazard identiﬁcation and compound prioritization as an
alternative/replacement of the in vitro chromosome aberration
test (CAT). This test has already gained widespread in-
ternational interest, as it offers signiﬁcant advantages over the
in vitro CAT. The in vitro MNT allows the detection of both
clastogens and aneugens and it can simultaneously detect
mitotic delay, apoptosis, chromosome breakage, chromosome
loss and non-disjunction (1,2). Different end points can be
regarded and used as biomarkers of DNA damage and therefore
the assay can be referred to as micronucleus cytome assay
providing additional important mechanistic information (3).
Furthermore, the scoring phase can be automated by ﬂow
cytometry and/or image analysis which beneﬁts screening
programmes. The in vitro MNT is a simple test method. Slide
reading is easy, more objective and quick, resulting in a much
higher throughput. Metaphase analysis is in contrast very
tedious, time consuming and has a low throughput. The in vitro
MNT has been shown to be a robust test which can be applied
to any type of primary cells or cell lines (4). Finally, it
has greater accuracy and statistical power as thousands of cells
can be scored compared to a few hundred in the in vitro CAT.
A limitation of the in vitro MNT is that the assay does not
provide information about the types of structural chromosome
aberrations.
Although an extensive amount of published data is available
to support the validity of the in vitro MNT using various cell
lines, primary cells or human lymphocytes, the in vitro MNT
assay is not yet generally accepted by regulatory authorities as
an alternative system in a test battery. One of the reasons is that
the in vitro MNT had not been formally validated. Therefore,
following a recommendation of an expert meeting on the
in vitro MNT held at the European Centre for the Validation of
Alternative Methods (ECVAM) in 2004, ECVAM conducted
this retrospective validation of the in vitro MNT. At the
meeting, the experts agreed that, given the considerable data on
the test already available and the high interest in using the test
for regulatory purposes, an evaluation of the existing data
should be undertaken to assess the validity on the in vitro MNT
as alternative to the in vitro CAT.
In order to evaluate whether the test met all data require-
ments requested by the ECVAM principles on test validity,
the modular approach of validation was followed (5). This
approach is deﬁned by seven validity modules: (1) test deﬁni-
tion, (2) within-laboratory reproducibility, (3) transferability,
(4) between-laboratory reproducibility, (5) predictive capacity,
(6) applicability domain and (7) minimum performance
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cover the reproducibility aspects of the assay, module 5 the
predictivity/concordance, module 6 the applicability domain
and module 7 deﬁnes the requirements to accept additional
data/assays for the same end point. Module 7 was not
considered, as this is a retrospective evaluation of data.
Here, we present the evaluation undertaken by the
Validation Management Team (VMT) established by ECVAM,
which led to the conclusions that the in vitro MNT is
a reproducible and reliable method to be used as an alternative
to the in vitro CAT. An ofﬁcial validation report had been
submitted earlier to ECVAM’s Scientiﬁc Advisory Committee
(ESAC), composed of representatives from all European Union
Member States, academia, industry and animal welfare
organizations for a peer review of the scientiﬁc validity of
the in vitro MNT [for ESAC statement see (6)].
Material and methods
Several studies (4,7–16) were discussed and evaluated by an Expert Group
during a meeting held at ECVAM, Italy, in April 2004. The analysis was
mainly based on the criteria for protocol requirements deﬁned by the Expert
Group (Supplementary Material, Appendix 1 is available at Mutagenesis
Online), the International Workshop on Genotoxicity Tests (IWGT) testing
recommendations (4) and the Organization for the Economical Cooperation and
Development (OECD) draft guideline [Test Guideline (TG) 487].
In the end, two data sets, the German ring trial (7) and the SFTG Ring Trial
(8,13–16) were considered to meet most, but not all, of the set criteria for the
ECVAM retrospective validation. Both studies were suitable for the analysis of
the within-laboratory reproducibility, the transferability and the between-
laboratory reproducibility, mainly due to their well controlled study set-up and
the availability of the raw data for an in-depth expert re-evaluation. The main
characteristics of the two studies are summarized in the Supplementary
Material, Appendix 2 (available at Mutagenesis Online). All other studies cited
above were only considered in the assessment of the concordance between the
in vitro MNT and the in vitro CAT and were used to support/strengthen or
negate the conclusions drawn by the VMT.
Evaluation of the studies for the assessment of reproducibility
The two studies used for re-evaluation of raw data were originally designed to
address different purposes. The aim of the German ring trial was mainly to
analyse the concordance between the in vitro MNT and the in vitro CAT. As it
was designed similarly to a prospective validation, a standardized protocol was
used in all participating laboratories. The main focus of the SFTG trial was to
assess the optimal protocol design and the reproducibility of different protocols
in several cell types. The raw data of the two studies were evaluated originally
by different expert groups. As a consequence, the criteria considered for
a positive call were not the same. In the German trial, biological relevance, a
concentration-related increase of the micronuclei (MN) frequency and repro-
ducibility of effects were the primary criteria for a positive call. In the SFTG
study, the primary criteria were a concentration-related increase of MN
frequency and a statistically signiﬁcant increase in the incidence of micro-
nucleated cells in treated samples over the solvent control. Taking the above
factors into account, it was evident that the data set was heterogeneous in
a way, which would complicate the comparison of data between studies. For
this reason and in order to acquire more conﬁdence in the data, it was
considered necessary to reanalyse the raw data of both studies. The use of
identical evaluation criteria led to a consistent call for both sets of raw data,
allowing an improved ﬁnal evaluation of the results.
The reanalysis of the raw data was conducted at ECVAM by experts who
had not been involved in the two studies. A consensus on the criteria for
a positive, negative and equivocal call was reached among the experts prior to
the evaluation of the raw data. The criteria were determined by taking into
account the following: (i) the criteria initially deﬁned by the expert group as if
they had to be applied in a prospective study, in a best case scenario
(Supplementary Material, Appendix 1 is available at Mutagenesis Online); (ii)
the criteria deﬁned in the draft OECD TG on the in vitro MNT (TG 487) and
(iii) the raw data available.
An early draft of the OECD TG 487 recommended the use of a test
concentration that produces up to 60% cytotoxicity. However, in the past,
concentrations which induce 50% cytotoxicity were used. Therefore, the VMT
decided to evaluate the raw data considering both 50 and 60% cytotoxicity,
allowing comparison of these two cytotoxicity criteria (Supplementary
Material, Appendix 4 is available at Mutagenesis Online). For the purpose of
the validity assessment of the in vitro MNT, only 60% cytotoxicity was
considered. Measures considered in the assessment of cytotoxicity were
proliferation index, mitotic index, viable cell count and, in the presence of
cytochalasin B, percentage of multinucleated cells.
Criteria for the evaluation of raw data and the judgement of the relevance of
effects
At the ﬁrst meeting, the expert group agreed on a series of evaluation criteria as
if they had been deﬁned for a prospective validation exercise. However, for this
retrospective validation exercise, not all criteria could be applied in every case.
Consequently, the criteria were overruled by an independent expert judgement
of the raw data.
Judgement of the biological relevance of the effects observed was applied
primarilyasthe criteriontoevaluatethedata.Thisisinline withthemaincriteria
to be considered according to the OECD TG for in vitro CAT and the draft
guideline for in vitro MNT. The measure to assess the biological relevance of
effectswastheoccurrenceofadoserelationshipandthemagnitudeoftheeffects.
Statistical methods may be used as an aid in evaluating the test results (OECD
guidelinesforinvitrosystems).Statisticalsigniﬁcancewasnotconsideredinthis
re-evaluation of raw data as it was available only for the SFTG trial.
Historical control data were not available for the studies, which made it
difﬁcult to judge the relevance of the relative increases of MN compared to
controls. However, the observed range of the negative controls (NCs) for each
laboratory in this series of experiments was used as an aid when judging the
relevance of effects.
A compound was called ‘positive’ if it clearly showed a dose-related
increase in MN frequency and the upper limit of the observed range of NC for
each laboratory had been exceeded. Likewise, a compound was ‘negative’ in
the in vitro MNT when there was no dose-related increase in MN frequency and
the upper limit of the observed range of NC for each laboratory had not been
exceeded. If the use of the above-described criteria did not allow judging the
individual experiment in question as positive, but the magnitude of the effect or
the observed dose relationship questioned the classiﬁcation of the test item as
negative, the study was rated ‘equivocal’. If in a study the required level of
toxicity (50 or 60%) was not reached and no positive response was obtained,
the study was rated as ‘not appropriate’ because it could not be excluded that at
a higher level of toxicity a positive result would have been obtained.
To be in line with both the draft OECD TG and the current protocol
requirements, the evaluation criteria in this evaluation were stricter than those
used in the respective papers. Therefore, following the re-evaluation of the raw
data, many experiments were re-categorized as not appropriate because at the
time it was not required to test up to the currently requested levels of cyto-
toxicity (at least 50%). A summary of the number of experiments, which were
not appropriate according to the deﬁned criteria, is shown in Supplementary
Material, Appendix 2 (Table A5, available at Mutagenesis Online).
In the SFTG study, the judgement was based on binucleated cells, if results
in both binucleated and mononucleated cells were available. This allowed the
comparison of results between all cell lines, including human lymphocytes. As
in the German trial, data on both proliferation index and mitotic index were not
consistently available, both parameters were considered equally adequate for
the determination of cytotoxicity.
An overview of the treatments and recovery times used in the two studies is
shown in Supplementary Material, Appendix 2 (Table A4, available at
Mutagenesis Online). For the schematic representation of all data collected and
re-evaluated by the VMT, see Supplementary Material, Appendix 2 (Table A6,
available at Mutagenesis Online).
Evaluation of the available data for the assessment of concordance between the
in vitro MNT and the in vitro CAT
The purpose of this retrospective validation is to determine whether the MNT in
vitro can be used as alternative to the in vitro CAT. The assessment of
concordance was based on the following studies and reviews of published data
selected by the expert group and the VMT (7,9–12).
MNT data. The in vitro MNT data of the German trial, reported in Table III,
represent the conclusions of the re-evaluation by the VMT. Regarding the study
of Miller et al. (10), the data reported represent the conclusions of the
Gesellschaft fu ¨r Umwelt-Mutationsforshung (GUM) working group. For the
other studies, the data are reported as they were published in the original pa-
pers. The data retrieved from the CGX database [(12), http://www.lhasalimited.
org/cgx] were ﬁltered out for the studies already described in the other data
sources considered, in order to avoid duplications.
CAT data. The data for in vitro CAT were reviewed by D. Kirkland (Covance,
UK), based on the published literature and expert judgement. In order to allow
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close as possible to those currently required for evaluation of in vitro CAT
under regulatory testing and therefore comparable to the criteria used for the
evaluation of the in vitro MNT in the studies considered. To achieve this, the
results of old studies were evaluated according to the current testing
requirements for genotoxicity testing (e.g. no test carried out above 10 mM).
In addition, if in vitro CAT was concluded negative, but only performed in the
absence of S9, these studies were considered inadequate for such a conclusion
and were designated technically compromised. Such results could not be
compared with the in vitro MNT results. In order for these judgements to be
made, the original papers (or the NTP database in the case of NTP studies) were
reviewed. Where necessary, literature searches were made through ToxLine
and PubMed in order to uncover other publications. Information on numerical
chromosome aberrations was, if available, included in Table III.
In cases with more than one experiment per compound, a positive result
(both in the presence and in the absence of S9) always overruled a negative,
equivocal or inconclusive result. Only when several negative results where
obtained together with only one positive result, the ﬁnal conclusion was
inconclusive. In case of negative results together with an equivocal or
inconclusive result, the ﬁnal conclusion was ‘inconclusive’.
Classiﬁcation of the compounds. All compounds reported in Table III were
classiﬁed into the following classes: clastogens, aneugens and non-genotoxic
substances. When the information was available, the compounds were also
classiﬁed as non-carcinogens. The classiﬁcation was based on the available
information present in the public domain and on expert judgement. The original
papers (or the NTP database in the case of NTP studies) were reviewed and,
where necessary, literature searches were made through ToxLine and PubMed
in order to uncover other publications that would deﬁne the predominant types
of activity. For some chemicals, the classiﬁcation of aneugen could only be
drawn from studies on non-mammalian systems such as on yeasts or other
fungi. Some chemicals that were quite weak clastogens (inconsistent responses
reported in literature or producing only borderline responses) were found to be
clearly more genotoxic in other tests for mutational end points, such as the
Ames or mouse lymphoma tests, and these are marked as such in Table III. The
classiﬁcation of the compounds was essentially carried out by D. Kirkland and
was subsequently reviewed by the genotoxicity Roche expert group. The
classiﬁcation allowed evaluating the in vitro MNT–CAT concordance overall,
as well as for each class of compounds separately.
Results
Within-laboratory reproducibility
The within-laboratory reproducibility assessment was based on
the expert re-evaluation of raw data (Supplementary material,
Appendix 2, Table A6 is available at Mutagenesis Online),
which took into account the 60% cytotoxicity criterion.
Repeat experiments were conducted in most of the
laboratories involved in the SFTG study and in some
laboratories involved in the German study (in certain instances
up to four times), allowing for the assessment of within-
laboratory reproducibility. It was considered appropriate to
conduct a descriptive analysis (based on biological relevance)
of the data instead of a statistical one. One reason being the
limited number of data points per each parameter.
Table I shows the within-laboratory reproducibility calcu-
lated for each treatment protocol and each cell line used in
identical and independent experiments conducted in the same
laboratory. For this evaluation, not appropriate data and
equivocal data were excluded as it was assumed that in
a prospective study (or in real life), experiments with results
being not appropriate or equivocal would have been repeated.
When the evaluation was carried out for each cell model and
treatment protocol, the within-laboratory reproducibility ranged
from 83 to 100%. The lowest value was found for the L5178Y
cells with the ‘Long Long’ treatment/recovery. The within-
laboratory reproducibility assessed per treatment, independent
from cell model, varied from 94 to 100%, while the
reproducibility per cell line, independent from treatment,
varied from 97 to 100%.
Between-laboratory reproducibility
The between-laboratory reproducibility was based on the
expert conclusion of the raw data re-evaluation, as in the case
of the within-laboratory reproducibility, and was assessed
taking into account the 60% cytotoxicity criterion.
Since most of the laboratories repeated the identical
experiment more than once, the following criteria were deﬁned
to reach a ﬁnal conclusion when the results of an identical
experiment conducted in the same laboratory were not
concordant: (i) in the case of a positive and an equivocal
experiment in the same laboratory, the ﬁnal conclusion was
positive and (ii) in the cases of negative and equivocal results
or positive and negative results, the ﬁnal conclusion was
inconclusive (Supplementary material, Appendix 2, Table A7
is available at Mutagenesis Online).
It has to be noted that in a retrospective validation, which is
based on published data, it is difﬁcult to achieve a balance
between clastogenic and non-clastogenic compounds. This
literature bias is due to the publication of predominantly
positive results. However, from the industry experience, it is
known that the negatives are correctly predicted (9).
The data on the between-laboratory reproducibility per
treatment protocol and per cell system are reported in Table II.
Not appropriate, inconclusive and equivocal data were
excluded, since in a prospective study (or in real life), an
experiment with such results would have to be repeated. The
Table I. Within-laboratory reproducibility for each treatment and each cell system (exclusion of not appropriate and equivocal data)
SFTG ring trial German ring trial
Without CB With CB Without CB
Treatment S S L L S S L L S þ S9
Recovery S L N L S L L N S
HL – – – – 8:8, 100% 7:7 100% 6:6, 100% – – 21:21 100%
L5178Y 4:4, 100% 6:6, 100% 5:5, 100% 6:6, 100% 4:4, 100% – 5:6, 83% – – 30:31 97%
CHL 13:13, 100% 8:8, 100% 11:12, 92% 6:7, 86% 9:9, 100% – 10:10, 100% – – 57:59, 97%
CHO 7:7, 100% 5:5, 100% 4:4, 100% 5:5, 100% 6:6, 100% – 5:5, 100% – – 27:27, 100%
V79 – – – – – – – 12:12, 100% – 12:12, 100%
24:24, 100% 19:19, 100% 21:21, 95% 17:18, 94% 27:27, 100% 7:7, 100% 26:27, 96% 12:12, 100%
S, short; L, long; N, no recovery; CB, cytochalasin B. Reference to Table A4 (available at Mutagenesis Online) for details on the treatment and recovery times: HL,
human lymphocytes; L5178Y, mouse lymphoma cells; CHL, Chinese hamster lung cells; CHO, Chinese hamster ovarian cells and V79, Chinese hamster lung
ﬁbroblasts.
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which gave reproducible results for each treatment and each
cell system, indicating also the number of chemicals eligible
for this analysis. The data reported refer to the experiments that
have been conducted in at least two laboratories. Only the
laboratories that conducted identical experiments at least two
times were considered.
The between-laboratory reproducibility assessed per treat-
ment, independent from cell line, varied between 86% (for
Long Long treatment) and 100%. The between-laboratory
reproducibility assessed per cell model, independent from
treatment, varied from 79% (for L5178Y) to 100%. Overall,
taking into account all cell models and the different treatments,
the between-laboratory reproducibility was 95%. Comparable
reproducibility results were observed when different treatment
protocols or cell lines were used, underlining the robustness of
the assay.
Transferability
In general, the test method can easily be performed in
a laboratory that is experienced in routine cell culture
techniques. No particular facilities are required. General cell
culture laboratory equipment and instruments are sufﬁcient to
perform the in vitro MNT. All supplies and reagents are readily
available on the market. As stressed in the in vitro MN testing
requirements, when human lymphocytes, are used they should
derive from non-smoking, young, healthy donors. The in vitro
MNT requires personnel trained for general cell biology and cell
culture activities (e.g. aseptic operations). The operator should,
in particular, be trained in the scoring of micronuclei. However,
the training requirements for a person to be competent in scoring
the slides are much less rigorous for in vitro MNT than for
metaphase analysis. As there is no requirement to count the
chromosomes in a metaphase preparation or to evaluate subtle
chromatid and chromosome damage, but only to determine
whether or not a cell contains a micronucleus, the scoring is
faster and the evaluation is more objective.
The successful transferability of the MNT in vitro is
demonstrated by the satisfactory results for the between-
laboratory reproducibility from the studies evaluated, which
included several naive laboratories.
Concordance analysis
In order to evaluate the overall concordance between the in vitro
MNT andtheinvitroCAT,all dataon thesubstancestestedboth
with in vitro MNT and in vitro CAT in the considered studies
were summarized in a single table (Table III). The table also
reports the type of cells used for the test and whether the test was
performed in the presence or absence of S9.
The studies considered in this analysis differ in several
characteristics such as the availability of raw data, whether or
not the in vitro MNT and in vitro CAT were conducted in
parallel within the same study, the quality of in vitro CAT
reference data considered, the use of proprietary compounds or
the number of compounds tested. As mentioned above, the
concordance between in vitro MNT and in vitro CAT was
analysed in each study separately and in addition by pooling all
data (Table VIII). Important information about the different
data sets considered and the concordance results for each of the
studies are described in Supplementary material, Appendix 3
(available at Mutagenesis Online).
In Table IV, the concordance analysis for the 113
compounds of Table III is shown. The concordance between
both assays was 83.2%. However, of the 92 in vitro MNT-
positive compounds, 9 were negative in the in vitro CAT assay.
Of these in vitro CAT-negative compounds, six are known as
pure aneugens. Consequently, they were correctly negative in
the in vitro CAT assay. Correcting the concordance for these
aneugens, the capacity of the in vitro MNT to predict
clastogens and aneugens was 88.5%.
Moreover, to allow a concordance analysis for each chemical
class, all compounds were classiﬁed in the following classes:
clastogens, aneugens and non-genotoxic (Tables V–VII).
While the concordance between in vitro MNT and in vitro
CAT is 77.8% for aneugens, the predictive capacity of MNT
was 100% for the set of aneugenic compounds evaluated. The
concordance for clastogens and non-genotoxins was 87.3 and
73.3%, respectively.
Table VIII summarizes the analysis of the performance of
the in vitro MNT in comparison to in vitro CAT overall for the
different classes of compounds and for each study. The
concordance for the different studies ranged between 80.8 and
88.9%.
Discussion
The primary focus of this ECVAM retrospective validation
using the modular validation approach (5) was to evaluate the
potential of the in vitro MNT to serve as alternative to the
standard in vitro CAT. Based on the data presented and
evaluated, the ECVAM VMT concluded that the in vitro MNT
meets all data requirements requested by the ECVAM
Table II. Between-laboratory reproducibility for each treatment and each cell system (exclusion of not appropriate, equivocal and inconclusive data)
SFTG ring trial German ring trial
Without CB With CB Without CB
Treatment S S L L S S L L S þ S9
Recovery S L N L S L L N S
HL – – – – 3:3, 100% 5:5, 100% 5:5, 100% – – 13:13, 100%
L5178Y 1:1, 100% 3:3, 100% 2:3, 67% 2:3, 67% 1:2, 50% – 2:2, 100% – – 11:14, 79%
CHL 5:5, 100% 4:4, 100% 5:5, 100% 2:2, 100% 4:4, 100% – 5:5, 100% – – 25:25, 100%
CHO 5:5, 100% 5:5, 100% 4:4, 100% 3:3, 100% 3:3, 100% – 4:4, 100% – – 24:24, 100%
V79 – – – – – – – 16:18, 89% 2:2, 100% 18:20, 90%
11:11, 100% 12:12, 100% 11:12, 92% 7:8, 86% 11:12, 92% 5:5, 100% 16:16, 100% 16:18, 89%
S, short; L, long; N, no recovery; CB, cytochalasin B; HL, human lymphocytes; L5178Y, mouse lymphoma cells; CHL, Chinese hamster lung cells; CHO, Chinese
hamster ovarian cells and V79, Chinese hamster lung ﬁbroblasts.
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Class Chemical CAS
No.
S9
mix
Cells,
MNT
MNT Overall
MNT
S9 Cells,
CAT
CAT Overall
CAT
References,
MNT
References,
CAT
SA NA
CL Acetaminophen 103-90-2   CHL þþ   Several þ  þ(11) (17)
CL Acetylsalicyclic acid (aspirin) 50-78-2   CHL Weak þþ   CHL þ  þ(11) (17)
CL 2-Acetylaminoﬂuorene 53-96-3 þ L5178Y þþ   /þ CHL þþ (18) (17)
  Several þ  RL1 þ (10) (17)
þ CHL þ  V79   (10) (17)
þ V79 þ (7)
CL Actinomycin D 50-76-0  /þ CHO þþ   Several þþ (19) (17)
  Several þ  Several þ (10) (10)
CL Adriamycin 25316-40-9   Several þþ   Several þþ (10) (10)
CL Aﬂatoxin B1 1162-65-8   MCL-5 þþ þ V79 þþ (20) (17)
  Several þ  Several þ (10) (10)
þ HULY þþ HULY þ (10) (10)
CL 2-Aminoanthracene 613-13-8   Several i þþ CHO E E (10) NTP database
þ Several þ (10)
CL 2-Amino-3,4-dimethylimidazo
-[4, 5-f]quinoline
77094-11-2 þ CHL þþ Not
given
CHL þþ (11) (11)
CL 2-Amino-1-methyl-6-phenylimidazo-
[4, 5-b]pyridine
105650-23-4 þ CHL þþ Not
given
CHL þþ (11) (11)
CL 2-Amino-3-methyl-9H-pyrido-[2, 3-b]
indole acetate
63170-60-5   CHL þþ Not
available
þþ þ(11) (21)
CL m-Amsacrine 54301-15-4   Several þþ   Several þþ (10) (10)
CL Aniline 62-53-3 þ CHL þþ þ CHL þ  þ(11) (17)
CL o-Anthranilic acid 118-92-3 þ CHO þþ þ CHO E E (22) NTP database
NG/NC L-ascorbic acid 50-81-7   CHO þþ   /þ CHO    (23) NTP database
CL Barbital 57-44-3   CHL Weak þþ   CHL þ  i (11) (17)
  DON   (17)
CL Benzene 71-43-2 þ CHL Weak þ i  /þ Several þ  þ(11) (17)
þ V79   (7)
CL Benzidine 92-87-5   MCL-5 þþ   /þ Several þþ (20) (17)
CL Benzoin 579-44-2 þ CHL Weak þþ þ CHL þ  þ(11) Concurrent test
a
CL Benzo[a]pyrene 50-32-8 þ CHL þþ þ CHL þ  þ(11) Concurrent test
a
  SHE/3T3 þ  Several   (10) (10)
þ Several þþ Several þ (10) (10)
CL Benzylchloride 100-44-7   CHL þþ   CHO þþ (11) (17)
  RL4 þ (17)
  HULY   (17)
NG/C Benzylacetate 140-11-4   V79 i i  /þ CHL    (7) (24)
CL Bleomycin sulphate 11056-06-7   V79 þþ   Several þþ (7) (17)
  Several þþ (10) (10)
NG/C
b N-butyl-N-(3-carboxypropyl)nitrosamine 38252-74-3   CHL Weak þþ   CHL     (11) (17)
CL Cadmium acetate 543-90-8   CHL þþ   HULY þþ (11) (17)
A/CL Cadmium chloride 10108-64-2   CHL þþ   Several þþ (11) (17)
  Several þ  CHO þ (10) (10)
þ HULY   (10)
CL Cadmium sulphate 10124-36-4   V79 þþ   HY þþ (7) (17)
A Carbendazim (methyl-2-
benzimidazole carbamate)
10605-21-7   V79 þþ HULY    (7) (10)
Several þ (10)
A Carbon tetrachloride 56-23-5   H2E1, MCL-5 þþ   /þ CHO    (25) NTP database
  AHH-1   (25)
CL Catechol 120-80-9   CHL þþ   SHE þþ (11) (26)
A/CL Chloral hydrate 302-17-0   V79 þþ   L5178Y þþ (27) (28)
  Several þ (10)
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Class Chemical CAS
No.
S9
mix
Cells,
MNT
MNT Overall
MNT
S9 Cells,
CAT
CAT Overall
CAT
References,
MNT
References,
CAT
SA NA
þ HULY   (10)
A Chlordane 57-74-9   Beluga whale skin
ﬁbroblasts
þþ   /þ CHO    (29) NTP database
CL m-Chloroaniline 108-42-9   CHL Weak þþ   CHL þþ þ(11) Concurrent test
a
CL p-Chloroaniline 106-47-8 þ CHL    þ CHL þ  þ(11) (17)
CL 2-Chloro-n-butyric acid 4170-24-5   CHL þþ   CHL þ  þ(11) Concurrent test
a
CL 2-(Chloromethyl)pyridine.HCl 6959-47-3 þ CHO þþ   /þ CHO þþ (22) NTP database
CL 2-Chloro-4-nitroaniline 121-87-9   CHL      HULY þþ (11) (30)
CL Chromic acetate 1066-30-4   CHL Weak þþ   HULY, CHO þ  þ(11) (17)
CL Chromic chloride 10025-73-7   CHL Weak þþ   HULY þ  i (11) (17)
  SH ﬁbroblasts   (17)
CL Ciproﬂoxacin 86393-32-0   CHO þþ   /þ CHO þþ (9) (9)
CL Ciproﬁbrate 52214-84-3   Rat hepatocytes þþ   Rat hepatocytes þþ (31) (32)
NG/C Cloﬁbrate 637-07-0   Rat hepatocytes      CHL þ i (33) (17)
  SHE   (34)
A/CL Colchicine 64-86-8   CHL þþ Not given þþ þ(11) (35)
  Several þ  CHO þ (10) (10)
CL Coumarin 91-64-5   Rat hepatocytes    þ CHO þþ (31) (36)
CL CP67804 None given   CHO þþ   CHO þþ (9) (9)
CL/A Cyclophosphamide hydrated and anhydrous 6055-19-2 þ CHL þþ þ CHL þ  þ(11) Concurrent test
a
50-18-0 þ V79 þ  /þ Several þ (7) (17)
  Several i þ Several þ (10) (10)
þ Several þ (10)
CL Cytosine arabinoside 147-94-4   V79 þþ   Several þþ (7) (17)
NG/C Dichlorodiphenyltrichloroethene 50-29-3   Beluga whale skin
ﬁbroblasts
þþ   B14F28 þ i (29) (17)
  V79   (17)
A N-deacetyl-N-methylcolchicine
(colcemid)
477-30-5   V79 þþ   CHL  þ þ
c (7) (37)
  CHL þþ (37) (36)
NG 3,5-Diaminobenzoic acid 535-87-5 þ CHL    Not given  
d    (11) (11)
CL/NC 2,6-Diaminotoluene.2HCl 15481-70-6  /þ CHO þþ   CHO þþ (23) NTP database
  CHO þ (38)
A Diazepam 439-14-5   V79 þþ   /þ Several    (27) (17)
  V79 þ  Several   (7) (10)
  Several þ (10)
CL/NC Diazinon 333-41-5   HULY E E þ CHL þþ (39) (17)
CL Dichloroacetic acid 79-43-6   L5178Y      L5178Y þþ (28) (28)
NG/C 1,4-Dichlorobenzene 106-46-7   Rat hepatocytes þ i  /þ CHO    (40) NTP database
  Human hepatocytes   (40)
CL/A 1,2-Dichloroethane 107-06-2   MCL-5, AHH-1, H2E1 þþ þ CHO þþ (25) NTP database
CL/A 1,2-Dichloropropane 78-87-5   MCL-5, AHH-1, H2E1 þþ   /þ CHO þþ (25) NTP database
NG/C Di(2-ethylhexyl)adipate 103-23-1   Rat hepatocytes      CHO E E (31) NTP database
NG/C Di(2-ethylhexyl)phthalate 117-81-7   Rat hepatocytes      /þ Several    (31) (17)
þ/  V79   (7)
A Diethylstilbestrol 56-53-1   V79 þþ   /þ Several þþ þ(7) (17)
  Several þ (10)
þ Several þ  Several i (10) (10)
Diethylstilbestrol (cis and trans) 6898-97-1   CHL þþ Several i (11) (10)
CL/NC Dimethoate [AKA
phosphorodithioic acid,o,o-
dimethyl ester,S-ester with
2-mercapto-N-methylacetamide]
60-51-5   HULY E E   CHL þþ (39) (17)
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Class Chemical CAS
No.
S9
mix
Cells,
MNT
MNT Overall
MNT
S9 Cells,
CAT
CAT Overall
CAT
References,
MNT
References,
CAT
SA NA
CL/A N,N-dimethylaniline 121-69-7   V79 þþ þ CHO þþ (41) (42)
CL 7,12-Dimethylbenz[a]anthracene 57-97-6 þ CHL þþ þ CHL þ  þ(11) Concurrent test
a
þ V79 þ  /þ Several þ (7) (17)
  SHE þ  /þ CHL E (10) (10)
þ Several þþ Several þ (10) (10)
CL Dimethylnitrosamine 62-75-9 þ CHL þþ þ CHL þ  þ(10) Concurrent test
a
NG/NC Dimethyl terephthalate 120-61-6 Not
given
HULY      /þ CHO    (43) (44)
  (43)
A Econazole 27220-47-9   Several   i No data   i (10) (35)
  Luc-2 E (45)
  Cl-1 þ (46)
CL Enroﬂoxacin 93106-60-6   CHO þþ   /þ CHO þþ (9) (9)
A 17-B-estradiol 50-28-2   HULY þþ   /þ HULY  þ þ
c (47) (17)
CL 2-Ethoxybenzamide 938-73-8   CHL þþ   CHL þþ þ(11) Concurrent test
a
CL/A Ethyl methanesulphonate 62-05-0   CHL þþ   Several þ  þ(11) (17)
  V79 þ  Several þ (7) (10)
  Several þ (10)
CL N-Ethyl-N#-nitro-N-
nitrosoguanidine
4245-77-6   CHL þþ   CHL þ  þ(11) (17)
CL N-Ethyl-N-nitrosourea 759-73-9   CHL Weak þþ   Several þ  þ(11) (17)
CL 5-Fluorouracil 51-21-8   CHL þþ   CHO/CHL þ  þ(11) (17)
  V79 E   Several þ (7) (10)
  Several þ (10)
þ CHL þ (10)
CL Fumonisin B1 116355-83-0   Rat hepatocytes þþ   Rat hepatocytes þþ (48) (48)
A Griseofulvin 126-07-8   Rat hepatocytes þþ   HULY, EUE þþ þ(31) (17)
  V79 þ  HULY E (7) (10)
  Several þ (10)
? Hexachlorobenzene 118-74-1   Rat hepatocytes þþ   CHL TC TC (40) (17)
  Human hepatocytes þ (40)
NG/C Hexachloroethane 67-72-1   MCL-5, AHH-1, H2E1        (25) NTP database
CL Hydrogen peroxide 7722-84-1   CHL þþ   Several þ  þ(11) (17)
A/CL Hydroquinone 123-31-9   CHL þþ   CHL þþ (11) Concurrent test
a
  V79 þ  CHO E (7) (10)
  Several þþ CHO þ (10) (10)
þ HULY   (10)
CL/NC Malathion 121-75-5   HULY þþ þ CHO þþ (49) (36)
NG/NC Maleic hydrazide 123-33-1  /þ HULY      HULY E E (50) (50)
CL 6-Mercaptopurine 50-44-2   CHL þþ   HULY, CHO, CHL þ  þ(11) (17)
CL Mercuric chloride 7487-94-7   HULY þ i   HULY þþ (51) (51)
 
CHL    FM3A TC   (11) (17)
CL/NC Methotrexate 59-05-2   V79 i i  /þ CHO, A(T1)CL-3 þþ (7) (17)
CL 3-Methylcholanthrene 56-49-5   MCL-5 þþ þ CHL, þþ (20) (17)
þ CHO    RL1 þ (10) (17)
þ CHL, L5178Y þ  CHL   (10) (10)
þ CHL, L5178Y þ (10)
G
e/C 4,4-Methylenebis(2-chloroaniline) 101-14-4   CHL Weak þþ   CHL  þ þ
c (11) Concurrent test
a
A Methylmercury chloride 115-09-3   CHL þþ   HULY þþ þ(11) (52)
CL Methyl methanesulphonate 66-27-3   CHL þþ   Several þ  þ(11) (17)
  Several þ  Several þ (10) (10)
G
e 2-Methyl-4-nitroaniline 99-52-5   CHL      CHL  þ þ
c (11) Concurrent test
a
CL/A N-Methyl-N#-nitro-N-nitrosoguanidine 70-25-7   CHL þþ   Several þ  þ(11) (17)
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Class Chemical CAS
No.
S9
mix
Cells,
MNT
MNT Overall
MNT
S9 Cells,
CAT
CAT Overall
CAT
References,
MNT
References,
CAT
SA NA
  Several þ  Several þ (10) (10)
CL 1-Methyl-1-nitrosourea 684-93-5   Several þþ   CHO þþ (10) (10)
NG Methylurea 598-50-5   V79      CHL, Don TC TC (7) (16)
CL Mitomycin C 50-07-7   CHL þþ   Several þ  þ(11) (17)
  V79 þ  Several þ (7) (10)
  Several þ (10)
CL Monocrotaline 315-22-0   Rat hepatocytes þþ þ CHO þþ (31) (17)
  Rat ﬁbroblasts   (17)
NG/C Nafenopin 3771-19-5   Rat hepatocytes      Rat hepatocytes þþ (31) (32)
NG/C Nalidixic acid 389-08-2   CHO      /þ CHO    (53) NTP database
  CHO    CHO   (9) (9)
CL b-Naphthoquinoline 85-02-9   CHL þþ   /þ CHL þþ (11) (17)
CL/NC N-(1-naphthyl)ethylenediamine.
2HCl [AKA PL-89779]
1465-25-4  /þ CHO    þ CHO þþ (22) NTP database
CL Neocarcinostatin 9014-02-2   Several þþ   Several þþ (10) (10)
CL Nickel acetate 373-02-4   CHL þþ   FM3A þþ (11) (17)
CL Nickel chloride 7718-54-9   CHL þþ   FM3A þþ (11) (17)
A Nitrilotriacetic acid 139-13-9   Cl-1 þþ   /þ CHO    (54) (42)
E o-Nitroaniline 88-74-4   CHL      /þ CHO i (11) (55)
CL/NC 4-Nitroanthranilic acid 619-17-0  /þ CHO    þ CHO þþ (22) NTP database
CL 2-Nitroﬂuorene 607-57-8   CHL Weak þþ þ CHL þ  þ(11) (56)
  Several þ  CHL E (10) (10)
þ CHL þþ CHL þ (10) (10)
CL/NC 4-Nitro-o-phenylenediamine 99-56-9  /þ CHO      CHMP/E þþ (22) (57)
G
e/NC 3-Nitropropionic acid 504-88-1  /þ CHO E E   CHO E E (22) NTP database
CL 4-nitroquinoline-N-oxide 56-57-5   L5178Y þþ   Several þþ (20) (17)
CL N-nitrosodiethylamine
(diethylnitrosamine)
55-18-5   Rat hepatocytes þþ þ CHL, CHO þþ (31) (17)
NG/C N-nitrosodiphenylamine 86-30-6  /þ CHO      /þ CHO    (58) (44)
CL m-Nitrotoluene 99-08-1   CHL Weak þþ   CHL TC þþ (11) (17)
  HULY þ (29)
CL o-Nitrotoluene 88-72-2   CHL þþ   CHL TC þþ (11) (17)
  HULY þ (30)
CL p-Nitrotoluene 99-99-0   CHL      CHL TC þþ (11) (17)
  HULY þ (30)
CL Norﬂoxacin   CHO      /þ CHO    (9) (9)
CL Oﬂoxacin 85344-55-4   CHO þþ   CHO þþ (9) (9)
A Oxazepam 604-75-1   SHE, AFFL, L5178Y þþ   /þ CHO    (59) NTP database
CL Phenacetin 62-44-2 þ CHL    þ CHL þþ (11) (17)
G
e Phenobarbital 50-06-6   Rat hepatocytes      /þ CHO, CH1-L þþ (31) (17)
CL/NC Phenol 108-95-2 þ CHL Weak þþ þ CHO þþ (11) (60)
 /þ CHO þ  CHO E (23) (10)
 /þ CHO þ (19)
  HULY þ (61)
CL Phenolphthalein 77-09-8   MCL-5 þþ þ CHO þþ (62) NTP database
CL m-Phenylenediamine 108-45-2   CHL þþ   CHL þ  þ(11) Concurrent test
a
CHL þ (17)
CL p-Phenylenediamine 106-50-3 þ CHL þþ þ CHL þ  þ(11) (17)
CL/NC p-Phenylenediamine.2HCl 624-18-0   CHO þþ   /þ CHO þþ (22) NTP database
CL Potassium bromate 7758-01-2   CHL þþ   CHL þ  þ(11) Concurrent test
a
  CHL þ (17)
NG/NC Promethazine.HCl 58-33-3 þ V79 E E  /þ CHO    (63) (36)
NG/NC Pyrene 129-00-0   V79      /þ Several    (7) (17)
R
.
C
o
r
v
i
e
t
a
l
.
2
7
8Table III. Continued
Class Chemical CAS
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  SHE, HepG2    CHL, CHO, DON   (10) (10)
þ CHO  þ CHO, CHL   (10) (10)
þ L5178Y   (18)
A/CL Pyrimethamine 58-14-0   AHH-1 þþ   HULY þþ (25) (64)
  CHL þ (10)
  V79 i   CHL þ (10) (10)
þ/  HULY  þ CHL   (10) (10)
? Retinol acetate 127-47-9   V79 þþ   CHL TC TC ( ) (7) (17)
A/NC Rotenone 83-79-4  /þ HULY þþ   /þ CHO  þ
c (5) (65)
 /þ HULY   (66)
  CHL  þ (67)
NG/C Safrole 94-59-7 þ L5178Y þþ þ CHL, CHO þþ (18) (17)
  Several   (17)
NG
d Sodium chloride 7647-14-5   CHL  
d    HULY TC TC (11) (17)
  16 MA þ
d   16 MA þ
d (68) (68)
NG/C Tetrachloroethylene 127-18-4   CHL      CHL     (11) Concurrent test
a
NG/C 12-o-Tetradecanoylphorbol-13-acetate 16561-29-8   CHL      CHL    i (11) Concurrent test
a
  HULY, Mouse PEC þþ (17)
  CHO, CHL   (17)
A Thiabendazole 148-79-8   V79 þþ   CHO, CHL TC þþ
c (7) (17)
  V79 þ (10)
 /þ HULY   (10)
NG/C Titanium dioxide 13463-67-7  /þ CHO      /þ CHO    (23) (60)
NG/C Toluene 108-88-3 þ/  V79 i i  /þ CHO    (7) NTP database
CL Triamterene 396-01-0   Don-6 þþ   CHL þþ (69) (17)
þ CHL   (17)
A 1,1,2-Trichloroethane 79-00-5   H2E1, MCL-5 þþ   /þ CHO þþ (25) NTP database
  AHH-1   (25)
A 1,1,2-Trichloroethylene (with
and without epichlorohydrin)
79-01-6   MCL-5 þ i   CHL     (25) (24)
  AHH-1    /þ CHO   (25) (36)
  V79    (7)
CL 1,2,3-Trichloropropane 96-18-4   MCL-5 þ i þ CHO þþ (25) NTP database
  H2E1, AHH-1   (25)
NG/NC Triphenyltin hydroxide 76-87-9 þ CHO þþ   /þ CHO    (22) NTP database
NG
d Urethane 51-79-6 þ CHL      CHL  
d    (11) (5)
  V79   (7)
A Vinblastine 143-67-9   CHL þþ   CHL  þ þ
c (11) Concurrent test
a
  V79 þ  Don þ (7) (70)
A Vincristine sulphate 5722-7   Several þþ   CHL þþ (10) (10)
CL, clastogens; A, aneugens; NG, non-genotoxic or equivocal; NC, non carcinogen; C, carcinogen; MNT, in vitro MNT; CAT, in vitro CAT; SA, structural aberrations; NA, numerical aberrations and TC, technically
compromised; NA was not always available; E, equivocal; i, inconclusive. Data on compounds that were reported in more than one publication (e.g. Ishidate and Miller) were reported only once. German trial results: re-
evaluation of the VMT. Cell type is reported only when available.
aChromosomal aberration tests were performed concomitantly under the same experimental condition.
bLack of clear genotoxicity may be due to unusual in vivo metabolism in tumour target tissue.
cThe overall call takes into consideration the numerical berration data.
dPositive results obtained only at the extremely high concentrations (.10 mM) were excluded.
eMore clearly genotoxic in systems other than those detecting A or CL.
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9principles on test validity and does fulﬁl the criteria for
a successful validation (Table IX). Therefore, the VMT
concluded that the in vitro MNT can be recommended as an
alternative/replacement for the in vitro CAT for genotoxicity
testing (hazard identiﬁcation). After a thorough peer review,
this conclusion was unanimously endorsed by all members of
the ESAC.
This evaluation demonstrated that the in vitro MNT has the
potential to reliably identify clastogens and to enhance the
basic battery of in vitro tests by its capability to detect
aneugens. Most of the established aneugens (deﬁned as in vivo
aneugens) have been tested with the in vitro MNT and scored
positive. ‘Pure’ aneugens were only positive in the in vitro
MNT and not in the standard in vitro CAT, if polyploidy and
chromosome count were not considered.
Nine chemicals tested were found to be positive only in the
in vitro CAT and not in the in vitro MNT. It is well known that
the in vitro CAT is prone to clastogenicity induction at high
toxicity levels. The effect has been discussed by several experts
to be irrelevant for the in vivo situation. One could now
speculate that the in vitro MNT is less prone to such non-
predictive positive effects. However, comparison to a ‘gold
standard’ always has the drawback that the assumption is made
that the results of this standard are 100% correct. Comparison
to carcinogenicity, for example, has the same limitations due to
the fact that carcinogenicity studies are rarely repeated and
the result obtained is always taken as 100% correct for
comparisons.
One of the main difﬁculties in a retrospective validation
study is the lack of a standardized protocol. As in the case of
the in vitro MNT evaluated in this retrospective validation, the
scopes of the available studies used were very different (7,8).
Based on these differences, the high reproducibility and
concordance found for the in vitro MNT underlines the
robustness of the test.
The outcome of this evaluation is a very important
contribution to the ECVAM validation process because for
the ﬁrst time a test has been validated based on existing data
only (retrospective validation) and will, therefore, lay the
ground for future retrospective validation studies. This
approach may be instrumental in the validation of alternative
methods that will contribute in ﬁnding more effective ways of
testing and assessing the toxicological and health impacts of
chemicals under the new European chemicals legislation
[Regulation Evaluation Authorisation of Chemicals
(REACH)].
Table VII. Concordance for compounds classiﬁed as non-genotoxic (NG)
MNT CAT
þ  Total
þ 1
a (6.5%) 3
b (20%) 4
  1
c (6.5%) 10 (67%) 11
Total 2 13 15
aSafrole.
bl-Ascorbic acid, n-butyl-N-(3-carboxypropyl)nitrosamine and triphenyltin
hydroxide.
cNafenopin.
Table IV. Concordance in vitro MNT/in vitro CAT for all compounds
MNT CAT
þ Total
þ 83 9
a 92
  10 11 21
Total 93 20 113
aCarbendazim, carbon tetrachloride, chlordane, diazepam, nitriloacetic acid and
oxazepam (all known as pure aneugenic compounds) were correctly negative in
the in vitro CAT but positive in the in vitro MNT.
Table V. Concordance for compounds classiﬁed as clastogenic (CL)
MNT CAT
þ  Total
þ 61 (86%) 0 61
  9
a (13%) 1
b (1%) 10
Total 70 1 71
ap-Chloroaniline (not convincingly clastogenic), 2-chloro-4-nitroaniline,
coumarin, dichloroacetic acid, 2-methyl-4-nitroaniline, N-(1-
naphthyl)ethylenediamine.2HCl, 4-nitroanthranilic acid, 4-nitro-o-
phenylenediamine and phenacetin.
bNorﬂoxacin.
Table VI. Concordance for compounds classiﬁed as aneugenic (A) or
aneugenic/clastogenic (A/CL)
MNT CAT
þ Total
þ 21 (78%) 6
a (22%) 27
  00 0
Total 21 6 27
aCarbendazim, carbon tetrachloride, chlordane, diazepam, nitrilotriacetic acid,
oxazepam—remark: all six compounds classiﬁed as pure aneugens (A).
Table VIII. Summary of the concordance evaluations
No
compounds
Concordance
%
Sensitivity
%
Speciﬁcity
%
All compounds 113 83.2 89.2 55.0
Clastogens
a 71 87.3 _ _
Aneugens
b 27 77.8 _ _
Non-genotoxic
c 15 73.3 _ _
German ring trial (7) 20 85.0 92.9 66.7
Miller et al. (9) 54 83.3 95 76.5
Japanese ring trial (11) 62 82.3 91.5 53.3
GUM Working group (10) 27 88.9 100 25
Kirkland et al. (12) 125 80.8 87.0 56.0
aNorﬂoxacin was negative in both assays whereas chloroaniline (not
convincingly clastogenic), 2-chloro-4-nitroaniline, coumarin, dichloroacetic
acid, 2-methyl-4-nitroaniline, N-(1-naphthyl)ethylenediamine2HCl, 4-
nitroanthranilic acid, 4-nitro-o-phenylenediamine and phenacetin were negative
in the in vitro MNT but positive in the in vitro CAT.
bCarbendazim, carbon tetrachloride, chlordane, diazepam, nitrilotriacetic acid
and oxazepam (all known as pure aneugenic compounds) were negative in the
in vitro CAT but positive in the in vitro MNT.
cNafenopin was negative in the in vitro MN but positive in the in vitro CAT, l-
ascorbic acid, n-butyl-N-(3-carboxypropyl)nitrosamine and triphenyltin
hydroxide were positive in the in vitro MNT but negative in the in vitro CAT
whereas only safrole was positive in both assays.
R. Corvi et al.
280The successful validation of the in vitro MNT and its
endorsement by the independent ESAC has led to European
Union regulatory acceptance and to the quick integration in the
genotoxicity testing requirements foreseen in the REACH
legislation. Currently, the ICH (International Conference on
Harmonisation for pharmaceuticals) is also considering rec-
ommending the in vitro MNT as an alternative to the in vitro
CAT and mouse lymphoma TK assay for the detection of
clastogenic/aneugenic potential based on the ‘validation status’
received by ECVAM. Furthermore, the formal (retrospective)
validation by ECVAM should support the ﬁnalization of the
TG and its regulatory acceptance by the OECD. OECD
acceptance of the in vitro MNT will lead to its widespread
international application.
Supplementary data
Supplementary material is available at Mutagenesis Online.
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